InnoCare Pharma, kampani yotsogola ya biopharmaceutical, yalengeza lero kuti wodwala woyamba adamwedwa muyeso lachipatala la Phase II la Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib pochiza primary immune thrombocytopenia (ITP) ku China.
Primary immune thrombocytopenia (ITP), yomwe imatchedwanso idiopathic thrombocytopenic purpura, ndi matenda omwe amapezeka ndi chitetezo chamthupi chomwe chimadziwika ndi kuchepa kwa zotumphukira zamapulateleti amagazi, zomwe zimapangitsa kuti chiwopsezo cha mikwingwirima ndi magazi chiwonjezeke[i]. Pathogenesis yayikulu ya ITP ndikutayika kwa kulekerera kwa chitetezo chamthupi ku mapulateleti a auto-antigen. Kusalolera kwa chitetezo chamthupi kumeneku kumabweretsa kuwonongeka kwa mapulateleti ndikuchepetsa kupanga kwa mapulateleti kuchokera ku megakaryocytes ndi ma autoantibodies ndi ma cytotoxic T lymphocytes.
Odwala pafupifupi 70% okha amayankha chithandizo chamankhwala choyamba, odwala ena akadali okanira kapena kubwereranso pambuyo pa mankhwala ophatikizana, choncho m'pofunika kufufuza zolinga zatsopano zochiritsira. Kuletsa kwa BTK kungachepetse kuwonongeka kwa mapulateleti poletsa kuyambitsa ma cell a B ndi kupanga ma autoantibody.
Zomwe zimachitika pachaka za ITP mwa akulu ndi pafupifupi 2-10 milandu yatsopano pa anthu 100,000[ii],[iii]. Okalamba opitilira zaka 60 ali pachiwopsezo chachikulu cha ITP, ndipo azimayi obereka ali pachiwopsezo chachikulu kuposa amuna azaka zomwezo.
Dr. Jasmine Cui, woyambitsa mgwirizano, Chairwoman ndi CEO wa InnoCare anati, "Palibe BTK inhibitor yomwe yavomerezedwa kuti ichiritse odwala omwe ali ndi ITP padziko lapansi. BTK ndi kinase yofunika kwambiri mu B cell receptor signing pathway, yomwe ndi yofunikira kuti ma lymphocyte B, macrophages ndi maselo ena a chitetezo ayambe kugwira ntchito komanso kupanga ma antibodies mu njira ya pathological ya ITP. Orelabrutinib ali ndi mwayi wosankha kwambiri wokhala ndi chitetezo, zomwe zikuyembekezeka kubweretsa njira zatsopano zothandizira odwala a ITP. "
ZOMWE MUNGACHITE PA NKHANIYI:
- BTK ndi kinase yofunika kwambiri mu B cell receptor signing pathway, yomwe ndi yofunikira kuti ma lymphocyte B, macrophages ndi maselo ena a chitetezo ayambe kugwira ntchito komanso kupanga ma antibodies mu njira ya pathological ya ITP.
- Primary immune thrombocytopenia (ITP), yomwe imatchedwanso idiopathic thrombocytopenic purpura, ndi matenda omwe amapezeka ndi chitetezo chamthupi omwe amadziwika ndi kuchepa kwa zotumphukira zamapulateleti amagazi, zomwe zimapangitsa kuti chiwopsezo cha mikwingwirima ndi kutuluka magazi chichuluke[i].
- Jasmine Cui, woyambitsa nawo, Wapampando ndi CEO wa InnoCare adati, "Palibe BTK inhibitor yomwe idavomerezedwa kuti azichiza odwala omwe ali ndi ITP padziko lapansi.
